[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627346":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":36,"centralContacts":67,"locations":76,"responsibleParty":103,"collaborators":10,"id":105,"slug":106,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":114,"minAge":10,"maxAge":10,"enrollmentInfo":115,"targetDuration":10,"studyType":118,"phases":10,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",[8,14,18,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"Postmenopausal healthy women with overweight\u002Fobesity.",[13],"Other: Observational study (baseline)",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","Postmenopausal healthy women with normoweight.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group 3","Postmenopausal women with breast cancer and overweight\u002Fobesity",[22],"Other: Observational study (baseline and 1 year)",{"label":24,"type":10,"description":25,"interventionNames":26},"Group 4","Postmenopausal women with breast cancer and normoweight.",[22],[28,32],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"Observational study (baseline)","Data will be collected at a single time point.",[9,15],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":10},"Observational study (baseline and 1 year)","Data will be collected at two time points during the study period.",[19,24],[37,41,43,46,48,50,52,54,56,58,61,63,65],{"name":38,"affiliation":39,"role":40},"Miguel Burgos, PhD","Center for Nutrition Research","PRINCIPAL_INVESTIGATOR",{"name":42,"affiliation":39,"role":40},"María Jesús Moreno-Aliaga, PhD",{"name":44,"affiliation":39,"role":45},"María Soledad García-Unciti, PhD","STUDY_CHAIR",{"name":47,"affiliation":39,"role":45},"Idoia Ibero-Baraibar, PhD",{"name":49,"affiliation":39,"role":45},"Iosune Zubieta",{"name":51,"affiliation":39,"role":45},"Salomé Pérez",{"name":53,"affiliation":39,"role":45},"Asunción Redín",{"name":55,"affiliation":39,"role":45},"Andrea Lara",{"name":57,"affiliation":39,"role":45},"María Pilar Lostao, PhD",{"name":59,"affiliation":60,"role":45},"Natalia Rodríguez-Spiteri, PhD","Clínica Universidad de Navarra",{"name":62,"affiliation":60,"role":45},"Begoña Olartecoechea, PhD",{"name":64,"affiliation":60,"role":45},"Ángel Vizcay, PhD",{"name":66,"affiliation":60,"role":45},"Marta Santisteban, PhD",[68,73],{"name":38,"role":69,"phone":70,"phoneExt":71,"email":72},"CONTACT","+34948425600","806225","mburgosloz@unav.es",{"name":42,"role":69,"phone":70,"phoneExt":74,"email":75},"806558","mjmoreno@unav.es",[77,93],{"facility":39,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"RECRUITING","Pamplona","Navarre","31008","Spain","ES",{"type":85,"coordinates":86},"Point",[87,88],-1.64323,42.81687,{"lat":88,"lon":87},[91,92],{"name":38,"role":69,"phone":70,"phoneExt":71,"email":72},{"name":42,"role":69,"phone":70,"phoneExt":74,"email":75},{"facility":60,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":94,"geoPoint":96,"contacts":97},{"type":85,"coordinates":95},[87,88],{"lat":88,"lon":87},[98,101],{"name":62,"role":69,"phone":99,"phoneExt":10,"email":100},"+34948 25 54 00","bolarteco@unav.es",{"name":64,"role":69,"phone":99,"phoneExt":10,"email":102},"avizcay@unav.es",{"type":104,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100627346","role-of-pro-resolving-lipid-mediators-in-obesity-associated-diseases-100627346",false,"NCT07447440","Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases","Unraveling the Role of Pro-Resolving Lipid Mediators of Inflammation and Their Receptors in Obesity-Associated Diseases: New Therapeutic Approaches for Maresin 1 (RESOLBE)","RESOLBE","HEALTHY PARTICIPANTS:\n\nInclusion Criteria:\n\n* Postmenopause (al least 1 year).\n* Normoweight or overweight\u002Fobesity.\n* No personal history of cancer.\n* Stable weight over the last 3 months (±5%).\n* Willing to sign the informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\n* Personal history of cancer.\n* Current weight loss treatment (diet, supplementation, surgery, others...).\n* Bariatric surgery.\n* No stable pharmacological treatment for at least 3 months.\n* Diabetes treatment and hormone replacement therapy.\n* Relevant functional or structural abnormalities of the gastrointestinal tract, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc.\n* High alcohol intake, more than 14 units per week for women and 20 units per week for men.\n* Surgical interventions resulting in permanent sequelae of the gastrointestinal tract.\n* Liver disease, except for non-alcoholic fatty liver disease.\n* Cognitive and\u002For psychiatric impairment.\n* Poor compliance or difficulty following study procedures.\n\nBREAST CANCER PARTICIPANTS:\n\nInclusion Criteria:\n\n* Postmenopause (at least 1 year).\n* Normoweight or overweight\u002Fobesity.\n* Luminal subtype breast cancer, stages I-II, who require tumor resection and do not require preoperative treatment.\n* Willing to sign the informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\n* Luminal subtype breast cancer stages over than II or other type of breast cancer.\n* Require preoperative treatment.",true,"FEMALE",{"count":116,"type":117},60,"ESTIMATED","OBSERVATIONAL","The main objective of this project is to determine the possible association between the levels of certain bioactive lipids, which the body produces from dietary fatty acids, and tumor characteristics in breast cancer patients, as well as their relationship with overweight\u002Fobesity.\n\nSpecific objectives are:\n\n* To analyse anthropometric and body composition changes.\n* To evaluate physical activity level.\n* To determine dietary profile.\n* To determine the adherence to Mediterranean dietary pattern.\n* To assess the quality of life.\n* To determine levels of specialized pro-resolving lipid mediators\n\nThe target sample size is 60 subjects. Participants will be allocated in four groups:\n\n* Group 1: Postmenopausal healthy women with overweight\u002Fobesity (n=15)\n* Group 2: Postmenopausal healthy women with normoweight (n=15)\n* Group 3: Postmenopausal women with breast cancer and overweight\u002Fobesity (n=15)\n* Group 4: Postmenopausal women with breast cancer and normoweight (n=15)",[121,122,123],"Breast Cancer","Health, Subjective","Obesity",[125,126,127,128,123],"Breast","Cancer","Postmenopause","Lipid mediators","2026-03-09",{"date":131,"type":132},"2026-03-11","ACTUAL",{"date":134,"type":132},"2025-10-15",{"date":136,"type":117},"2027-12-30",{"name":5,"class":6},2]